<DOC>
	<DOCNO>NCT01872988</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) one common solid cancer worldwide , chronic hepatitis B virus ( HBV ) infection common etiology HCC Asia . Transarterial chemoembolization ( TACE ) standard treatment patient unresectable HCC BCLC intermediate stage , HCC recurrence rate long-term mortality rate quite high . These intermediate-staged HCC patient usually need repeated TACE due tumor recurrence , may die HCC progression liver decompensation repeat TACE . Improved liver function decrease liver disease progression due oral antiviral therapy proven effective chronic hepatitis B , oral antiviral therapy may keep good liver reserve provide good chance HCC patient receive TACE . In addition , chronic HBV infection one important factor HCC development , antiviral therapy improve outcome curative treatment . However , evidence improve outcome HCC patient underwent TACE oral antiviral therapy lacking . Moreover , Tenofovir Disoproxil Fumarate ( TDF ) one potent oral antiviral agent , safety low long-term viral resistance rate also report . There study evaluate impact TDF HBV-related HCC patient underwent TACE . Until , routine antiviral therapy HBV-related HCC patient underwent TACE still recommend current guideline . The hypothesis study potent oral antiviral therapy patient HBV-related HCC patient receive TACE improve patient ' outcome</brief_summary>
	<brief_title>Tenofovir Antiviral Therapy Following Transarterial Chemoembolization HBV Related Hepatocellular Carcinoma</brief_title>
	<detailed_description>This randomized double-blind placebo-controlled trial conduct referral teaching hospital Taiwan . This trial recruit 320 patient fulfil follow criterion : patient 20 year old , HCCs diagnose AASLD image criterion pathology , medium-sized HCCs BCLC intermediate stage 5 cm maximum diameter 5 tumor TACE indicate , chronic HBV carrier ( HBsAg+ ) detectable HBV DNA blood , ECOG performance status ( PST ) 0-2 , Child-Pugh score ≦7 , serum bilirubin &lt; 2 mg/dL prothrombin time ( PT ) prolongation &lt; 3 second , willingness adhere treatment follow-up plan . Patients ineligible follow exclusion criterion : vascular invasion tumor , extra-hepatic metastasis , concurrent malignancy , concomitant immunosuppressive therapy , previous HCC treatment , previous current antiviral therapy HBV , concomitant therapy HCC except TACE , liver cirrhosis severe gastroesophageal varix ( EVF3 red color sign ) , poorly-controlled ascites hepatic encephalopathy , contraindication invasive procedure recent gastrointestinal bleeding cerebral hemorrhage , contraindication TACE allergy contrast , pregnancy , sepsis , etc. , chronic renal failure eGFR &lt; 60 , concurrent chronic viral hepatitis HCV , HDV , HIV ) . The Primary endpoint study 1- , 3-year overall survival , secondary endpoint study time tumor progression time liver decompensation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. 20 year old 2 . HCCs diagnose AASLD image criterion pathology 3 . Intermediatestage HCCs TACE indicate 4. chronic HBV carrier detectable HBV DNA blood 5 . ECOG performance status ( PST ) 02 6 . ChildPugh score ≦7 7. serum bilirubin &lt; 2 mg/dL 8. prothrombin time prolongation &lt; 3 second 9. willingness adhere treatment followup plan 1. vascular invasion tumor 2. extrahepatic metastasis 3. concurrent malignancy 4. concomitant immunosuppressive therapy 5 . HCC recurrence within 2 year previous curative treatment 6. antiviral therapy chronic hepatitis B within 6 month HCC diagnosis 7. concomitant therapy HCC except TACE 8. liver cirrhosis severe gastroesophageal varix ( EVF3 red color sign ) , poorlycontrolled ascites hepatic encephalopathy 9. contraindication invasive procedure recent gastrointestinal bleeding cerebral hemorrhage 10. contraindication TACE allergy contrast , pregnancy , sepsis , etc . 11. chronic renal failure eGFR &lt; 60 12. concurrent chronic viral hepatitis HCV , HDV , HIV )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>antiviral therapy</keyword>
	<keyword>intermediate stage</keyword>
	<keyword>hepatitis B virus</keyword>
</DOC>